Recruiting

Moda-flx Hemodialysis

Sponsor:

Diality Inc.

Code:

NCT06613568

Conditions

End Stage Kidney Disease

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Moda-flx Hemodialysis System™

Study Details

Brief summary:

The purpose of this study is to evaluate the safety and efficacy of the Moda-flx Hemodialysis System™ when used Under Professional Care Settings by trained individuals and At Home by trained Participants and Care Partners

Conditions

End Stage Kidney Disease

Study ID

NCT06613568

Start date

Oct 6, 2025

Status verified date

Aug, 2025

Completion date

Sep, 2027

Anticipated

Primary completion date

Mar, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Are between 18 and 80 years of age and Care Partner is at least 18 years of age at the time of signing consent.
  • Have a diagnosis of end stage kidney disease (ESKD) adequately treated by maintenance dialysis (defined as achieving a spKt/V ≥ 1.2 OR stdKt/V ≥ 2.1) and be deemed stable by their treating nephrologist prior to the end of the Screening Period
  • Have a well-functioning and stable vascular access (tunneled central venous catheter arteriovenous fistula, or graft) that allows a blood flow of at least 300 ml/min prior to the end of Screening
  • Can successfully complete a Skills and Comprehension Assessment with a Care Partner prior to the completion of the Training Period.

Exclusion Criteria:

  • Hgb level of < 9 g/dL at Screening
  • Symptomatic intradialytic hypotension requiring medical intervention (ultrafiltration turned off, bolus of fluid) in at least two treatments during the Run-In period defined as:

1. Persistent pre-dialysis sitting SBP < 100 mmHg despite medical therapy,
2. Nadir intradialytic Systolic Blood Pressure (SBP) < 90 mmHg, if Subject's pre-HD SBP < 160 mmHg
3. Nadir intradialytic SBP < 100 mmHg if Subject's pre-HD SBP ≥ 160 mmHg
  • Documented history of non-adherence to dialysis therapy that would prevent successful completion of the study
  • Participant had an average ultrafiltration rate > 13 mL/kg/hour during the last 2 weeks prior to Screening, per medical records.
  • Had a significant cardiovascular adverse event within the last 90 days prior to Screening.

Study Design

Enrollment

50 participants

Anticipated

Intervention Model

Single group

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: Professional Care and At Home

Participants will receive dialysis therapy using the Moda-Flx Hemodialysis System™ in a Professional Care setting and At Home setting

Interventions

Moda-flx Hemodialysis System™

The Moda-flx Hemodialysis System™ is a portable hemodialysis system

Primary outcome measure

  • Weekly Standardized Dialysis Adequacy [ Time Frame: Up to 10 weeks per period ]
  • Adverse Event (AE) Rate [ Time Frame: Up to 10 weeks per period ]

Central Contacts and Locations

Central contacts

Locations

North America Research Institute

Recruiting

San Dimas, California, United States, 91773

Contacts

New York Kidney Hypertension Medicine

Recruiting

New Hyde Park, New York, United States, 11040

Contacts

Nephrology Associates of Knoxville

Recruiting

Knoxville, Tennessee, United States, 37920

Contacts

aQua Research Institute, LLC

Recruiting

Houston, Texas, United States, 77058

Contacts

University of Washington

Recruiting

Seattle, Washington, United States, 98104

Contacts

Lori Linke

linkel@uw.edu

More Information

Sponsor

Diality Inc.

Last update posted

Jul 6, 2026

Last verified

Aug, 2025

Keywords

  • Renal Disease
  • Hemodialysis Complication
  • Kidney Diseases
  • Dialysis
  • Renal Dialysis
  • Hemodialysis, Home
  • Renal Insufficiency
  • Kidney Failure, Chronic

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Diality Inc. on 2026-07-06.